Duchenne Muscular Dystrophy Drugs Market Report

Japan Duchenne Muscular Dystrophy Drugs Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Sep 17, 2019
  • PAGES：182
  • REPORT CODE：GMM286135
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Duchenne Muscular Dystrophy Drugs market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Duchenne Muscular Dystrophy Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Duchenne Muscular Dystrophy Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.


    By Player:

    • Acceleron Pharma

    • Janssen Pharmaceuticals

    • Catabasis Pharmaceuticals

    • Asklepios BioPharmaceuticals

    • BioMarin Pharmaceutical

    • Pfizer

    • Nippon Shinyaku

    • Lexicon Pharmaceuticals

    • Santhera Pharmaceuticals

    • Sarepta Therapeutics

    • Summit Therapeutics

    • Capricor Therapeutics

    • PTC Therapeutics

    • Nobelpharma

    • Taiho Pharmaceutical

    • Akashi Therapeutics

    • Italfarmaco

    • Bristol-Myers Squibb

    • Eli Lilly

    • Marathon Pharmaceuticals


    By Type:

    • Exondys51

    • Translarna

    • Emflaza


    By End-User:

    • Hospitals

    • Home care settings

    • Clinics


    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Duchenne Muscular Dystrophy Drugs Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Exondys51 from 2014 to 2026

      • 1.3.2 Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Translarna from 2014 to 2026

      • 1.3.3 Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Emflaza from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

      • 1.4.2 Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Home care settings from 2014 to 2026

      • 1.4.3 Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026


    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants


    3 Segmentation of Duchenne Muscular Dystrophy Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Duchenne Muscular Dystrophy Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Exondys51

      • 3.4.2 Market Size and Growth Rate of Translarna

      • 3.4.3 Market Size and Growth Rate of Emflaza

    4 Segmentation of Duchenne Muscular Dystrophy Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Duchenne Muscular Dystrophy Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Duchenne Muscular Dystrophy Drugs in Hospitals

      • 4.4.2 Market Size and Growth Rate of Duchenne Muscular Dystrophy Drugs in Home care settings

      • 4.4.3 Market Size and Growth Rate of Duchenne Muscular Dystrophy Drugs in Clinics


    5 Market Analysis by Regions

    • 5.1 Japan Duchenne Muscular Dystrophy Drugs Production Analysis by Regions

    • 5.2 Japan Duchenne Muscular Dystrophy Drugs Consumption Analysis by Regions


    6 Hokkaido Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 6.1 Hokkaido Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 6.2 Hokkaido Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    7 Tohoku Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 7.1 Tohoku Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 7.2 Tohoku Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    8 Kanto Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 8.1 Kanto Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 8.2 Kanto Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    9 Chubu Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 9.1 Chubu Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 9.2 Chubu Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    10 Kinki Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 10.1 Kinki Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 10.2 Kinki Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    11 Chugoku Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 11.1 Chugoku Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 11.2 Chugoku Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    12 Shikoku Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 12.1 Shikoku Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 12.2 Shikoku Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    13 Kyushu Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 13.1 Kyushu Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 13.2 Kyushu Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users


    14 Major Players Profiles

    • 14.1 Acceleron Pharma

      • 14.1.1 Acceleron Pharma Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Janssen Pharmaceuticals

      • 14.2.1 Janssen Pharmaceuticals Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Catabasis Pharmaceuticals

      • 14.3.1 Catabasis Pharmaceuticals Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 Asklepios BioPharmaceuticals

      • 14.4.1 Asklepios BioPharmaceuticals Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 BioMarin Pharmaceutical

      • 14.5.1 BioMarin Pharmaceutical Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 Pfizer

      • 14.6.1 Pfizer Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Nippon Shinyaku

      • 14.7.1 Nippon Shinyaku Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Lexicon Pharmaceuticals

      • 14.8.1 Lexicon Pharmaceuticals Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Santhera Pharmaceuticals

      • 14.9.1 Santhera Pharmaceuticals Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 Sarepta Therapeutics

      • 14.10.1 Sarepta Therapeutics Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 Summit Therapeutics

      • 14.11.1 Summit Therapeutics Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 Capricor Therapeutics

      • 14.12.1 Capricor Therapeutics Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 PTC Therapeutics

      • 14.13.1 PTC Therapeutics Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Nobelpharma

      • 14.14.1 Nobelpharma Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Taiho Pharmaceutical

      • 14.15.1 Taiho Pharmaceutical Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 Akashi Therapeutics

      • 14.16.1 Akashi Therapeutics Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

    • 14.17 Italfarmaco

      • 14.17.1 Italfarmaco Company Profile and Recent Development

      • 14.17.2 Market Performance

      • 14.17.3 Product and Service Introduction

    • 14.18 Bristol-Myers Squibb

      • 14.18.1 Bristol-Myers Squibb Company Profile and Recent Development

      • 14.18.2 Market Performance

      • 14.18.3 Product and Service Introduction

    • 14.19 Eli Lilly

      • 14.19.1 Eli Lilly Company Profile and Recent Development

      • 14.19.2 Market Performance

      • 14.19.3 Product and Service Introduction

    • 14.20 Marathon Pharmaceuticals

      • 14.20.1 Marathon Pharmaceuticals Company Profile and Recent Development

      • 14.20.2 Market Performance

      • 14.20.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 149 Figures and 149 Tables)

     

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Exondys51 from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Translarna from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Emflaza from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Home care settings from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Duchenne Muscular Dystrophy Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Duchenne Muscular Dystrophy Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Duchenne Muscular Dystrophy Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Duchenne Muscular Dystrophy Drugs by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Exondys51

    • Figure Market Size and Growth Rate of Translarna

    • Figure Market Size and Growth Rate of Emflaza

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Duchenne Muscular Dystrophy Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Duchenne Muscular Dystrophy Drugs by Different End-Users from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Home care settings from 2014 to 2026

    • Figure Japan Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Table Japan Duchenne Muscular Dystrophy Drugs Production by Regions

    • Table Japan Duchenne Muscular Dystrophy Drugs Production Share by Regions

    • Figure Japan Duchenne Muscular Dystrophy Drugs Production Share by Regions in 2014

    • Figure Japan Duchenne Muscular Dystrophy Drugs Production Share by Regions in 2018

    • Figure Japan Duchenne Muscular Dystrophy Drugs Production Share by Regions in 2026

    • Table Japan Duchenne Muscular Dystrophy Drugs Consumption by Regions

    • Table Japan Duchenne Muscular Dystrophy Drugs Consumption Share by Regions

    • Figure Japan Duchenne Muscular Dystrophy Drugs Consumption Share by Regions in 2014

    • Figure Japan Duchenne Muscular Dystrophy Drugs Consumption Share by Regions in 2018

    • Figure Japan Duchenne Muscular Dystrophy Drugs Consumption Share by Regions in 2026

    • Table Hokkaido Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Hokkaido Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Hokkaido Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Tohoku Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Tohoku Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Tohoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Kanto Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Kanto Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Kanto Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Chubu Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Chubu Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Chubu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Kinki Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Kinki Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Kinki Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Chugoku Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Chugoku Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Chugoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Shikoku Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Shikoku Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Shikoku Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Kyushu Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2014

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2018

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by Types in 2026

    • Table Kyushu Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2014

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2018

    • Figure Kyushu Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of Acceleron Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Acceleron Pharma

    • Figure Sales and Growth Rate Analysis of Acceleron Pharma

    • Figure Revenue and Market Share Analysis of Acceleron Pharma

    • Table Product and Service Introduction of Acceleron Pharma

    • Table Company Profile and Development Status of Janssen Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Janssen Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Janssen Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Janssen Pharmaceuticals

    • Table Product and Service Introduction of Janssen Pharmaceuticals

    • Table Company Profile and Development Status of Catabasis Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Catabasis Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Catabasis Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Catabasis Pharmaceuticals

    • Table Product and Service Introduction of Catabasis Pharmaceuticals

    • Table Company Profile and Development Status of Asklepios BioPharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Asklepios BioPharmaceuticals

    • Figure Sales and Growth Rate Analysis of Asklepios BioPharmaceuticals

    • Figure Revenue and Market Share Analysis of Asklepios BioPharmaceuticals

    • Table Product and Service Introduction of Asklepios BioPharmaceuticals

    • Table Company Profile and Development Status of BioMarin Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BioMarin Pharmaceutical

    • Figure Sales and Growth Rate Analysis of BioMarin Pharmaceutical

    • Figure Revenue and Market Share Analysis of BioMarin Pharmaceutical

    • Table Product and Service Introduction of BioMarin Pharmaceutical

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Nippon Shinyaku

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nippon Shinyaku

    • Figure Sales and Growth Rate Analysis of Nippon Shinyaku

    • Figure Revenue and Market Share Analysis of Nippon Shinyaku

    • Table Product and Service Introduction of Nippon Shinyaku

    • Table Company Profile and Development Status of Lexicon Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Lexicon Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Lexicon Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Lexicon Pharmaceuticals

    • Table Product and Service Introduction of Lexicon Pharmaceuticals

    • Table Company Profile and Development Status of Santhera Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Santhera Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Santhera Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Santhera Pharmaceuticals

    • Table Product and Service Introduction of Santhera Pharmaceuticals

    • Table Company Profile and Development Status of Sarepta Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sarepta Therapeutics

    • Figure Sales and Growth Rate Analysis of Sarepta Therapeutics

    • Figure Revenue and Market Share Analysis of Sarepta Therapeutics

    • Table Product and Service Introduction of Sarepta Therapeutics

    • Table Company Profile and Development Status of Summit Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Summit Therapeutics

    • Figure Sales and Growth Rate Analysis of Summit Therapeutics

    • Figure Revenue and Market Share Analysis of Summit Therapeutics

    • Table Product and Service Introduction of Summit Therapeutics

    • Table Company Profile and Development Status of Capricor Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Capricor Therapeutics

    • Figure Sales and Growth Rate Analysis of Capricor Therapeutics

    • Figure Revenue and Market Share Analysis of Capricor Therapeutics

    • Table Product and Service Introduction of Capricor Therapeutics

    • Table Company Profile and Development Status of PTC Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of PTC Therapeutics

    • Figure Sales and Growth Rate Analysis of PTC Therapeutics

    • Figure Revenue and Market Share Analysis of PTC Therapeutics

    • Table Product and Service Introduction of PTC Therapeutics

    • Table Company Profile and Development Status of Nobelpharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nobelpharma

    • Figure Sales and Growth Rate Analysis of Nobelpharma

    • Figure Revenue and Market Share Analysis of Nobelpharma

    • Table Product and Service Introduction of Nobelpharma

    • Table Company Profile and Development Status of Taiho Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Taiho Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Taiho Pharmaceutical

    • Figure Revenue and Market Share Analysis of Taiho Pharmaceutical

    • Table Product and Service Introduction of Taiho Pharmaceutical

    • Table Company Profile and Development Status of Akashi Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Akashi Therapeutics

    • Figure Sales and Growth Rate Analysis of Akashi Therapeutics

    • Figure Revenue and Market Share Analysis of Akashi Therapeutics

    • Table Product and Service Introduction of Akashi Therapeutics

    • Table Company Profile and Development Status of Italfarmaco

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Italfarmaco

    • Figure Sales and Growth Rate Analysis of Italfarmaco

    • Figure Revenue and Market Share Analysis of Italfarmaco

    • Table Product and Service Introduction of Italfarmaco

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of Marathon Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Marathon Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Marathon Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Marathon Pharmaceuticals

    • Table Product and Service Introduction of Marathon Pharmaceuticals

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US